Abstract
Emerging studies have demonstrated the potential of PI3Kδ blockade as an immunotherapy for solid tumours. In pre-clinical models, we recently demonstrated that anti-LAG3 immune checkpoint blockade vastly potentiated PI3Kδ-based immunotherapy, enabling successful tumour control in all treated mice.
© 2021. The Author(s).
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Antigens, CD / immunology*
-
Class I Phosphatidylinositol 3-Kinases / immunology*
-
Drug Resistance, Neoplasm / drug effects
-
Drug Synergism
-
Humans
-
Immune Checkpoint Inhibitors / pharmacology*
-
Immune Checkpoint Inhibitors / therapeutic use
-
Immunotherapy
-
Lymphocyte Activation Gene 3 Protein
-
Mice
-
Neoplasms / drug therapy*
-
Neoplasms / immunology
-
Tumor Microenvironment
-
Xenograft Model Antitumor Assays
Substances
-
Antigens, CD
-
Immune Checkpoint Inhibitors
-
Class I Phosphatidylinositol 3-Kinases
-
PIK3CD protein, human
-
Lymphocyte Activation Gene 3 Protein